Brief: Hanmi's Oral Delivery Platform Compound Licensed to Gilead
29/09/2025 10:54
Sept 29 (Reuters) - Hanmi Science Co Ltd 008930.KS: HANMI'S ORAL DELIVERY PLATFORM COMPOUND LICENSED TO GILEAD HANMI SCIENCE CO LTD - CO AND HHP GRANT GILEAD EXCLUSIVE LICENSE TO ENCEQUIDAR Source text: ID:nPn5PYRHPa Further company coverage: 008930.KS ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hanmi Science Co
See all newsBrief: Hanmi Science Q1 Operating Profit 33.6 Billion Won, Up 24% From Year Earlier
Brief: Hanmi Science Q4 Operating Profit 37.6 Billion Won, Up 197.4% From Year Earlier
Brief: Hanmi Science Q3 Operating Profit 39.3 Billion Won, Up 75% From Year Earlier
Brief: Hanmi's Oral Delivery Platform Compound Licensed to Gilead
Brief: Hanmi's Oral Delivery Platform Compound Licensed to Gilead